Daiichi Sankyo disclosed it has returned to Translational Sciences the rights to TS23, an experimental blood clot dissolving agent. The monoclonal antibody product will still be developed, according to Translational Sciences.
NanoCellect Biomedical received $10 million from a Series B funding round that will be used to support initiatives relevant to the commercialization and development of microfluidic cell sorting technologies to be applied in fields such as antibody discovery, genomic sample preparation and CRISPR gene editing.
The Leukemia & Lymphoma Society is earmarking $46 million for blood cancer research globally. The nonprofit will provide grants to dozens of research projects, with many focusing on unusual approaches to treating a number of blood conditions, including myeloma.
Antiretroviral therapy-naive youths with HIV and confirmed tuberculosis had a 65% two-month survival rate by six months, compared with 83.5% for those with either unconfirmed or unlikely TB, according to a French study in The Lancet HIV. Researchers also found reduced mortality risk among those with either confirmed or unconfirmed TB who began anti-TB treatment as well as those who began ART during the first month of follow-up, while confirmed TB, miliary features, increased serum transaminases, and age younger than 2 years were linked to higher odds of death.
Challenges such as funding shortfalls and political turmoil are endangering the World Health Organization's initiatives to reduce malaria incidence and mortality by 40% by 2020, according to WHO's 2017 World Malaria Report. The report estimates there were 216 million malaria cases in 2016, compared with 237 million in 2010 and 210 million in 2015, though malaria mortality dropped from 537,000 deaths in 2010 to 440,000 in 2016.
Sanofi's dengue vaccine may worsen the disease in patients who have never been exposed to the virus, according to follow-up data from clinical trials. The company is proposing to national regulatory agencies that use be limited to people with previous infections.
Researchers from the Gurdon Institute of the University of Cambridge in the UK and other organizations used CRISPR-Cas9 gene-editing technology to identify the METTL3 gene as a possible drug target for acute myeloid leukemia, according to a study in the journal Nature. The investigators found that the protein produced by the gene enables the production of proteins essential to acute myeloid leukemia cells.
Quebec-based GenePOC has gained approval from the FDA to market its Clostridium difficile test GenePOC CDiff, which can detect the toxin B gene in toxigenic strains of C. diff.
Takeda Pharmaceutical launched an early-stage trial to evaluate TAK-426, its Zika virus vaccine candidate. Preliminary data from the Phase I study is expected to become available in 2018, with the goal of initiating Phase II studies as soon as possible if positive results are obtained.